Choosing the Right Drug Name How to Increase Your Chances for Approval

Held Nov. 12, 2009

The FDA can shut down your next promising product due to nothing more than a single letter of its name. They already reject 40% of proposed drug names. How can you up your odds?

You’ve invested in the bench science, locked down the clinical trial data and have pulled together the application ― all you need now is a hot product name.

But that should be a snap. Consult a Latin dictionary, hold an employee naming contest, convene a brainstorming session ... you’ll have your new name in three, four months tops.


Wrong, wrong, wrong. In truth, such methods are recipes for disaster, says brand consultant Jeff Gregory. He ought to know. He was in on the naming of Viagra®, Epogen®, Ambien®, Restasis® and many other blockbuster drugs.

Order this audio CD/Transcript, where Gregory took 90 minutes out of his busy schedule to initiate you into the secrets of drug-naming.

You’ll discover:

  • How one wrong letter can trigger FDA action, adding years and millions of extra dollars in expenses to your product launch
  • Why naming contests and brainstorming can actually lead to spending more on drug-naming consultants
  • The top 5 deal-killers in drug naming ― and how to steer clear of them
  • How close you can come to the line ― without crossing it ― in descriptive and benefit-driven drug naming
  • What to not even consider in drug naming

Gregory will debunk the urban legends about what brand names really mean ... how the X, Y and Z craze began ... how to position a brand in terms of the target audience, not the science ... and that’s just the beginning. You’ll learn:

  • Best practices for approaching a brand-name development project
  • Why the last FDA nomenclature director got the nickname Dr. Boring
  • Latest news from the FDA’s Proprietary Name Pilot Program
  • And why drug naming is so much harder than it looks

There are reasons that savvy drug and biologic companies spend $1 million ... $2 million ... even $3 million naming a new drug ... why they bring naming consultants on board at the earliest stages of clinical testing ... why the FDA rejects 40% of proposed drug names each year.

It costs you millions when the FDA delays your launch campaign. That’s not a risk worth taking — especially when you can pick the brain of one of the brainiest drug-namers around. Because it’s web-based, this 90-minute session is totally interactive — meaning you get your every question answered by the time you log off.

As many staffers may participate from one location as you like, all for one low registration fee. So don’t skimp — make sure every employee on your product development team participates, including:

  • Sales and marketing personnel
  • Compliance officers
  • Regulatory and legislative affairs professionals
  • R&D staff
  • Executive management
  • General and corporate counsel
  • Risk management specialists
  • Strategic planning and business development staff
  • Consultants and service providers
  • Personnel new to the industry

Phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Jeff Gregory is CEO and chief brand strategist at Brand Counsel, LLC. His firm brands exclusively in the life science and technology markets worldwide. A 23-year veteran of the drug and device industries, Mr. Gregory has been involved in blockbuster drug launches including Viagra®, Epogen®, Ambien®, Restasis® and many more. Mr. Gregory began his career in technology marketing and brand positioning with AT&T’s BellSouth and was previously managing director of The Brand Institute.

Order now!